ProMIS Neurosciences, Inc. PMN
Regular-session close
After hours · Nov 19, 4:37 PM ET
- YTD
- -53.00%
- 1 year
- -69.43%
5D -1.01 (-23.93%)
- Market cap
- 28.88M
- EPS (ttm)
- -6.50
- Shares out
- 32.69M
- Forward P/E
- -1.51
- YTD return
- -53.00%
- 1-year return
- -69.43%
- 50-day average
- 0.9886
- 200-day average
- 1.51
- Enterprise value
- 28.70M
- Volume
- 172.34K
- Avg volume
- 160.88K
- Open
- 3.39
- Previous close
- 3.13
- Day's range
- 3.02 – 3.45
- 52-week range
- 2.78 – 27.40
- Beta
- 0.61
- Analysts
- Strong Buy
- Price target
- 7.65 (+138.3%)
Key statistics
- Price / book
- 4.62
- Free cash flow
- -12.77M
- Total cash
- 1.02M
- Short % of float
- 1.04%
Fundamental scorecard
6 of 25 checks passed on PMN’s reported financials
6of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.14 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | -0.13 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -0.19 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- promisneurosciences.com
News
HC Wainwright & Co. Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price Target
ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline ProMIS Neurosciences Q3 EPS $(0.89) Beats $(1.28) Estimate
ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing
ProMIS Neurosciences to Participate in Upcoming Conferences in November
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026 Roth Capital Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $15
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
Your note
Sign in to keep a note on PMN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CASHMAN NEIL | Officer and Director | Stock Award(Grant) | Aug 22, 2023 | 114,921 |
| FARFEL GAIL M | Chief Executive Officer | Stock Award(Grant) | Aug 22, 2023 | 55,192 |
| GORDON MICHAEL STEPHEN | Beneficial Owner of more than 10% of a Class of Security | Purchase | Sep 16, 2024 | 2,217,180 |
| KIRWIN PATRICK D | Director | Purchase | Aug 13, 2024 | 99,096 |
| MALENFANT GAVIN T. | Chief Operating Officer | Stock Award(Grant) | Aug 22, 2023 | 2,660 |
| MILBURY MAX A. | Officer | Stock Award(Grant) | Aug 22, 2023 | 14,997 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Great Point Partners LLC | 8.54% | 2,790,698 | 2.57M | Sep 29, 2024 |
| Armistice Capital, LLC | 8.17% | 2,670,000 | 2.46M | Sep 29, 2024 |
| Sphera Funds Management Ltd. | 5.90% | 1,929,297 | 1.77M | Sep 29, 2024 |
| Ally Bridge Group (NY) LLC | 4.87% | 1,592,605 | 1.47M | Sep 29, 2024 |
| Altium Capital Management, LP | 1.78% | 581,395 | 534.88K | Sep 29, 2024 |
| Heights Capital Management, Inc | 1.18% | 386,894 | 355.94K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.03% | 8,622 | 7.93K | Oct 30, 2024 |
